Discontinuation of Odanacatib and Other Osteoporosis Treatments: Here Today and Gone Tomorrow?

被引：11

作者：

Bauer, Douglas C. ^{[1
,2
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94107 USA

[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2011年 / 26卷 / 02期

关键词：

CATHEPSIN-K INHIBITOR; LONG-TERM EXTENSION; LOW BONE-DENSITY; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; ALENDRONATE; BMD;

D O I：

10.1002/jbmr.335

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：239 / 241

页数：3

共 15 条

[1]

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].

Black, Dennis M. ;

Schwartz, Ann V. ;

Ensrud, Kristine E. ;

Cauley, Jane A. ;

Levis, Silvina ;

Quandt, Sara A. ;

Satterfield, Suzanne ;

Wallace, Robert B. ;

Bauer, Douglas C. ;

Palermo, Lisa ;

Wehren, Lois E. ;

Lombardi, Antonio ;

Santora, Arthur C. ;

Cummings, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938

[2]

BLACK DM, 2010, J BONE MINER RES S1, V25

[3]

Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].

Bone, Henry G. ;

McClung, Michael R. ;

Roux, Christian ;

Recker, Robert R. ;

Eisman, John A. ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Santora, Arthur C. ;

Ince, B. Avery .

JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947

[4]

Bone HG, 2009, J BONE MINER RES S1, V24

[5]

Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect [J].

Eisman, John A. ;

Bone, Henry G. ;

Hosking, David J. ;

McClung, Michael R. ;

Reid, Ian R. ;

Rizzoli, Rene ;

Resch, Heinrich ;

Verbruggen, Nadia ;

Hustad, Carolyn M. ;

DaSilva, Carolyn ;

Petrovic, Romana ;

Santora, Arthur C. ;

Ince, B. Avery ;

Lombardi, Antonio .

JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (02) :242-251

[6]

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension [J].

Ensrud, KE ;

Barrett-Connor, EL ;

Schwartz, A ;

Santora, AC ;

Bauer, DC ;

Suryawanshi, S ;

Feldstein, A ;

Haskell, WL ;

Hochberg, MC ;

Torner, JC ;

Lombardi, A ;

Black, DM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1259-1269

[7]

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation [J].

Garnero, P ;

Ferreras, M ;

Karsdal, MA ;

Nicamhlaoibh, R ;

Risteli, J ;

Borel, O ;

Qvist, P ;

Delmas, PD ;

Foged, NT ;

Delaissé, JM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (05) :859-867

[8]

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis [J].

Garnero, P ;

SornayRendu, E ;

Chapuy, MC ;

Delmas, PD .

JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (03) :337-349

[9]

Femoral neck bone loss predicts fracture risk independent of baseline BMD [J].

Nguyen, TV ;

Center, JR ;

Eisman, JA .

JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) :1195-1201

[10]

Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians [J].

Qaseem, Amir ;

Snow, Vincenza ;

Shekelle, Paul ;

Hopkins, Robert, Jr. ;

Forciea, Mary Ann ;

Owens, Douglas K. .

ANNALS OF INTERNAL MEDICINE, 2008, 149 (06) :404-W77

← 1 2 →